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Abstract
The risk of drug interactions with concurrent use of multiple medications is a clinically relevant
issue. Many patients are unaware that over-the-counter (OTC) analgesics can cause potentially
serious adverse effects when used in combination with other common medications such as
anticoagulants, corticosteroids, or antihypertensive agents. Of particular significance is the
increased risk of upper abdominal gastrointestinal adverse events in patients who take traditional
nonsteroidal anti-inflammatory drugs (NSAIDs). This risk is dose dependent and further increased
in patients who take more than one NSAID or use NSAIDs in combination with certain other
medications. Some NSAIDs may also mitigate the antiplatelet benefits of aspirin and may increase
blood pressure in patients with hypertension. Clinicians should be aware of potential drug
interactions with OTC analgesics when prescribing new medications. Additionally, patients should
be properly counseled on the appropriate and safe use of OTC analgesics.
Introduction
A survey of medication use patterns in the United States
has found that more than 80% of American adults used at
least one over-the-counter (OTC) or prescription drug
each week, and that 25% used at least 5 [1]. The OTC anal-
gesics acetaminophen, ibuprofen, and aspirin are among
the most frequently utilized medications, used by approx-
imately 17% to 23% of the population each week.
Chronic OTC analgesic use is most common in the eld-
erly, many of whom take nonsteroidal anti-inflammatory
drugs (NSAIDs) or acetaminophen for relief of pain. In
addition, a recent survey reported that approximately
50% of American adults classified as having high cardio-
vascular (CV) risk status take low-dose aspirin for CV
prophylaxis [1-3].
Because of the widespread availability and perceived
safety of OTC analgesics, self-medication with these
agents has become commonplace. Many patients are una-
ware of the potential for toxicity and adverse drug interac-
tions associated with the long-term and inappropriate use
of OTC analgesics. They may use OTC analgesics in
higher-than-recommended doses or in combinations that
magnify the risk of adverse interactions. Additionally,
patients may not be aware that common cough, cold, or
flu medications can contain OTC analgesics. Although
OTC analgesics are associated with adverse effects in only
a small percentage of people, the widespread use of these
drugs makes even a small increase in population risk a
clinically relevant issue [4]. Physicians can help patients
avoid possible drug-drug interactions with commonly
used OTC analgesics by providing counseling on the
proper use of these agents.
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Currently available OTC oral analgesics and 
mechanisms of action
There are currently 4 OTC oral analgesics available in the
United States: acetaminophen, aspirin, ibuprofen, and
naproxen [5]. When taken as recommended, these OTC
analgesics present relatively safe, effective, and economi-
cal treatments for mild to moderate pain, inflammation,
and fever. Nevertheless, as a result of their accessibility
and presumed safety, OTC analgesics are among the most
commonly ingested drugs in overdoses [6].
Acetaminophen is generally considered to exert its analge-
sic effects through the inhibition of prostaglandin (PG)
synthesis in the central nervous system [7], although the
exact mechanism is not clearly defined. Several recent
studies [7,8] have suggested alternative pathways, includ-
ing peripheral elevation of the pain threshold. Aspirin and
other NSAIDs inhibit the cyclooxygenase (COX) enzyme,
thereby decreasing synthesis of PGs and related com-
pounds that contribute to the inflammatory response and
mediate a variety of cellular functions [9,10]. Traditional
NSAIDs are nonselective for the 2 subtypes of the COX
enzyme, although aspirin is 170-fold more potent in
inhibiting COX-1 than COX-2 [9]. Whereas COX-1 inhi-
bition by traditional NSAIDs is reversible, aspirin com-
pletely inactivates and irreversibly inhibits platelet COX-
1, thus preventing formation of thromboxane A2[2,9].
Potential drug interactions with OTC analgesics
Several potential drug-drug interactions should be consid-
ered when OTC analgesics are used in combination with
other drugs (Table 1). In this article, these interactions are
classified into 3 main groups: 1) increased gastrointestinal
(GI) bleeding risk; 2) interference with the antiplatelet
effects of aspirin; and 3) other potential interactions and
issues.
Increased GI bleeding risk
Inhibition of COX by aspirin and other NSAIDs interferes
with the production of protective mucosal PGs [9]. This
mechanism likely explains the increased incidence of gas-
tric ulcers and upper GI bleeding with use of NSAIDs.
Listed below are several risk factors that increase the like-
lihood of developing GI toxicity with NSAIDs use [11-13]:
￿ Advanced age
￿ History of GI events
￿ Increased NSAID dose or multiple NSAID use
￿ Concomitant aspirin use.
Elderly patients are at greater risk of developing GI com-
plications and often have comorbidities that require anal-
gesic treatment [14]. Thus, careful monitoring of the
amount of OTC and prescription NSAID consumption is
imperative in the management of elderly patients. To
minimize GI adverse events, proton-pump inhibitors
(PPIs) or other gastroprotective agents may be useful for
patients who require NSAIDs for anti-inflammatory ther-
apy and are at risk for increased GI events [14,15].
COX inhibition by aspirin results in a dramatic reduction
of gastroprotective PGs in the GI tract, which explains the
dose-dependent increase in GI adverse effects with higher
doses of aspirin (odds ratio [OR] = 1.5 – 3.1) [16-18]. Sev-
eral studies have reported that the use of enteric-coated
Table 1: Potential drug interactions with OTC analgesics[5,42,43]
Drug combinations Effect Management options/considerations
Aspirin and NSAIDs or multiple NSAIDs Increased risk of serious GI complications. Risk 
increases with increased dose and number of 
agents
Avoid concurrent use of more than one NSAID, if 
possible. Consider adding gastroprotective agents
Anticoagulants and NSAIDs Increased risk of bleeding (especially GI) and 
increased oral warfarin activity
Avoid concurrent use of NSAID; monitor 
prothrombin time and occult blood in urine and 
stool
Corticosteroids and NSAIDs Increased GI side effects, including ulceration and 
hemorrhage
Avoid concurrent use of NSAID and consider 
adding a gastroprotective agent
SSRIs and NSAIDs Increased risk of GI bleeding Avoid concurrent use of NSAID
Aspirin and ibuprofen or naproxen Reduced antiplatelet effects of aspirin Not seen with other NSAIDs or acetaminophen
Antihypertensive agents and NSAIDs Use of NSAIDs may increase blood pressure Monitor blood pressure and cardiac function
Antidiabetic agents (eg, sulfonylureas) and 
aspirin
Increased hypoglycemic effect Avoid concurrent use and monitor blood glucose 
concentration
Lithium and NSAIDs Increased steady-state lithium concentration and 
lithium toxicity
Monitor lithium concentrations. Interactions are 
less likely with aspirin than with naproxen or 
ibuprofen
Methotrexate and NSAIDs Reduced renal clearance. Increased plasma 
methotrexate concentration
Avoid NSAIDs with high-dose methotrexate
GI = gastrointestinal; NSAID = nonsteroidal anti-inflammatory drug; OTC = over the counter; SSRI = selective serotonin reuptake inhibitor.Osteopathic Medicine and Primary Care 2008, 2:2 http://www.om-pc.com/content/2/1/2
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and buffered low-dose aspirin does not appear to decrease
the risk of GI adverse events (relative risk [RR], range =
2.3–2.7 {1.6–3.2}) [18-20]. Similarly, traditional NSAIDs
are also associated with a 2- to 4-fold increased risk of GI
side effects [11,16]. A summary of the risks for upper GI
bleeding from a case-control study that included aspirin,
acetaminophen, and ibuprofen, is shown in Figure 1[16].
Increased risk of GI adverse effects was observed with use
of aspirin and ibuprofen, but not with acetaminophen.
Adverse GI effects are further compounded by the use of
more than one agent and with higher NSAID doses
[11,13,16]. Concomitant use of aspirin and traditional
NSAIDs can double the risk of GI toxicity, as reported in a
study of low-dose aspirin used for CV prophylaxis [18].
The standardized incidence rate of upper GI bleeding was
2.6 (95% confidence interval [CI]: 1.8–3.5) for patients
using low-dose aspirin alone and 5.6 (95% CI: 4.4–7.0)
for those using low-dose aspirin in addition to traditional
NSAIDs. Gutthann and colleagues [11] reported much
higher incidence of upper GI bleeding or perforation in
patients who used multiple NSAIDs (adjusted OR = 9.0
[95% CI: 5.9–13.6]).
Although there is little inherent risk of GI events with anti-
coagulant use, several studies have shown that concomi-
tant treatment with aspirin and other NSAIDs can increase
the risk of GI hemorrhage and perforation [12,13]. This
may be linked to the impairment of platelet aggregation
induced by aspirin and nonselective NSAIDs [21]. A study
by Shorr and colleagues [12] reported a nearly 13-fold
increase (95% CI: 6.3–25.7) in risk of developing hemor-
rhagic peptic ulcer disease with concurrent use of NSAIDs
and anticoagulants in patients aged 65 years and older. A
similar study conducted in patients aged 25 to 80 years
reported an adjusted relative risk (RR) of 6.4 (95% CI:
2.8–14.6) for developing upper GI bleeding and perfora-
tion in patients using an NSAID and an anticoagulant,
compared with those who had not received either drug
[13].
Corticosteroids may cause decreased gastric mucus pro-
duction and delayed healing of NSAID-induced erosions
[22]. The use of corticosteroids in patients not receiving
NSAIDs is linked to a modest increase in GI events (OR
range, 1.1 – 2.3) [11,22]. Nevertheless, there is wide
reporting in the literature of a dramatic increase in the risk
of adverse GI effects, including ulceration and hemor-
rhage, with concomitant current use of corticosteroids
and NSAIDs (OR range, 2.2 – 14.6, in various studies)
[11,13,22]. Piper and colleagues (1991) demonstrated
that patients receiving corticosteroids (eg, cortisone 25
mg, hydrocortisone 20 mg, prednisolone 5 mg, pred-
nisone 5 mg) in combination with NSAIDs had a 15 times
greater risk for peptic ulcer disease than that of nonusers
of either drug. Thus, although corticosteroids may not
inherently increase the risk of GI toxicity, they exacerbate
the risk posed by NSAIDs by delaying the healing of
NSAID-induced ulcers.
Selective serotonin reuptake inhibitors (SSRIs) have been
associated with an increased risk of upper GI bleeding
[23,24]. Serotonin is essential in initiating the hemostatic
response of platelets to vascular injury [25]. By blocking
platelet uptake of serotonin, SSRIs may attenuate their
function. Thus, SSRIs may impair hemostatic function
and exacerbate underlying GI conditions when used con-
comitantly with drugs that cause GI ulceration and bleed-
ing (eg, NSAIDs) [23]. A recent case-control study
reported a low risk of GI adverse events with use of SSRIs
(OR = 1.30 [95% CI: 1.13–1.50], compared with nonuse
of SSRIs or NSAIDs), but confirmed an increased risk with
concomitant use of NSAIDs (OR = 4.19 [95% CI:
3.30–5.31], compared with nonuse of either drug) [25].
Acetaminophen may be an effective alternative to NSAIDs
for patients who require an analgesic and who are on con-
comitant aspirin, anticoagulant, corticosteroid, or SSRI
therapy. Patients should be educated on the risk factors
for developing adverse GI events with use of NSAIDs and
on appropriate ways to minimize further risks.
Interference with the antiplatelet effects of aspirin
Many patients use low-dose aspirin for primary or second-
ary prevention of myocardial infarction and stroke. Aspi-
rin induces irreversible COX-1 inhibition in the platelet, a
process that in turn inhibits the formation of thrombox-
ane A2 and prevents platelet aggregation (Figure 2) [2,26].
Because aspirin completely inactivates platelet COX-1,
The risk for upper GI bleeding with aspirin, ibuprofen, and  acetaminophen (adapted from reference [4], with permis- sion) Figure 1
The risk for upper GI bleeding with aspirin, ibuprofen, and 
acetaminophen (adapted from reference [4], with permis-
sion). OTC = over the counter.
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antiplatelet benefits last for the lifetime of the platelet and
are only attenuated by the regeneration of new platelets.
As a result, even low doses of aspirin may provide benefi-
cial CV effects. Nevertheless, recent studies have shown
that traditional NSAIDs may interfere with the antiplatelet
effects of aspirin by providing competition for the platelet
COX-1 binding site [26-28]. This may limit the utility of
aspirin as a cardioprotective agent in patients who require
certain NSAIDs to manage pain effectively.
Numerous studies have shown that ibuprofen interferes
with the antiplatelet effects of aspirin [26,28,29]. Catella-
Lawson and colleagues [26] evaluated whether the
antiplatelet effects of aspirin were mitigated by the con-
current use of ibuprofen, diclofenac, rofecoxib, and aceta-
minophen. Ibuprofen, administered as a single 400 mg
dose given before aspirin (81 mg) or as 3 400 mg doses
after a single 81 mg dose of aspirin, blocked the irreversi-
ble inhibition of platelet aggregation by aspirin. In con-
trast, the concomitant administration of rofecoxib (25 mg
once daily), diclofenac (75 mg twice daily), or acetami-
nophen (1000 mg once daily) – administered either
before or after a dose of aspirin – did not affect the inhibi-
tion of platelet aggregation by aspirin. Another study
The effect of aspirin alone and of ibuprofen plus aspirin on platelet cyclooxygenase-1 (COX-1) Figure 2
The effect of aspirin alone and of ibuprofen plus aspirin on platelet cyclooxygenase-1 (COX-1). A) The platelet prostaglandin 
(PG) G/H synthase-1 (COX-1) is depicted as a dimer, and the arachidonic acid substrate gains access to the catalytic site 
through a hydrophobic channel that leads to the core of the enzyme. B) Aspirin works by inhibiting access of arachidonic acid 
to the catalytic site by irreversibly acetylating a serine residue at position 529 in platelet COX-1. Interpolation of the bulky 
acetyl residue then permanently prevents metabolism of arachidonic acid into the cyclic endoperoxides PGG2 and PGH2. 
Because PGH2 is metabolized by thromboxane synthase into thromboxane A2, aspirin prevents the formation of thromboxane 
A2 by the platelets until new platelets are created. C) Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are 
competitive inhibitors of the catalytic site, and cause the reversible inhibition of thromboxane A2 formation during the dosing 
interval. Therefore, prior occupancy of the catalytic site by ibuprofen prevents aspirin from gaining access to its target serine 
(reproduced from reference [26], with permission).
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reported an increased risk in recurrent acute myocardial
infarction with prolonged use of ibuprofen and aspirin
compared with use of aspirin alone (hazard ratio for dura-
tion of exposure for at least 60 days = 1.83 [0.76–4.42])
[28]. Patients who take ibuprofen in addition to low-dose
aspirin for CV prophylaxis should be mindful of the
potential for drug interactions that may undermine the
cardioprotective benefits of aspirin.
Recent studies on the effect of naproxen on platelet and
vascular prostanoid inhibition have yielded inconclusive
results [27,30]. Unlike aspirin, naproxen inhibits prosta-
cyclin synthesis, the clinical implication of which is cur-
rently unknown. Nonetheless, naproxen is commonly
suggested as an alternative to ibuprofen in patients with
established CV risk who take daily low-dose aspirin for CV
prophylaxis [15]. Other alternatives for analgesia for
patients receiving long-term low-dose aspirin therapy
include acetaminophen or other NSAIDs such as
diclofenac, which do not preferentially inhibit COX-1.
Because acetaminophen is a weak inhibitor of COX-1, it
does not interfere with aspirin-mediated antiplatelet
effects [7].
Other potential interactions and issues
By inhibiting prostaglandin synthesis, NSAIDs can induce
sodium retention and vasoconstriction [31]. Clinical
studies have linked the use of NSAIDs to elevated blood
pressure, particularly in patients with a history of hyper-
tension who are already on antihypertensive medications
[32-35]. In a meta-analysis of randomized trials studying
the effect of NSAIDs on blood pressure, NSAIDs raised
mean blood pressure by 5.0 mm Hg [34]. Patients who
were concomitantly using β-blockers experienced greater
elevations in mean blood pressure (6.2 mm Hg) com-
pared with those using either vasodilators or diuretics.
Careful monitoring of blood pressure and cardiac func-
tion is therefore recommended for hypertensive patients
when initiating NSAID therapy. The potential risk of CV
events with use of NSAIDs has been studied extensively in
recent years. In 2005, the US Food and Drug Administra-
tion issued a request that manufacturers of all nonaspirin
NSAIDs, including COX-2 inhibitors, revise package
inserts to include a black box warning highlighting the
increased risk for CV events and GI bleeding with use of
these drugs [36].
Other medications may have adverse interactions when
taken in conjunction with OTC analgesics (Table 1). Aspi-
rin, particularly in combination with anticoagulation
therapy, has been shown to increase the risk of intracere-
bral hemorrhages (ICH) [37]. Although ICH is an uncom-
mon adverse effect of aspirin, the morbidity associated
with this condition makes it a clinically relevant issue.
Concomitant use of NSAIDs and antidiabetic agents, par-
ticularly sulfonylureas, may increase the risk of transient
hypoglycemia [38]. NSAIDs have also been shown to
increase risk of lithium and methotrexate toxicity by
increasing drug concentrations to unsafe levels [39-41].
Monitoring drug concentrations and adjusting dosages
when necessary may reduce the likelihood of adverse drug
interactions with use of OTC analgesics.
Approach to patient management
The following stepwise approach may be useful in the
management of patients who routinely use OTC analge-
sics (Table 2) [15]. In a patient who has no established CV
risk factors, with low or no NSAID GI risk, and who is not
taking aspirin, nonselective NSAIDs may be used to man-
age pain or inflammation. For a patient who has no CV
risk factors but who is at risk for NSAID-induced GI bleed-
ing, a COX-2 selective inhibitor may be prescribed. Alter-
natively, the clinician may choose to prescribe a
nonselective NSAID with a PPI or, in the case of a patient
who has had prior GI bleeding, a COX-2 selective inhibi-
tor with a PPI. Acetaminophen may be recommended for
patients at risk for GI events or for those who have a his-
tory of adverse effects with aspirin or NSAID use.
Table 2: Clinicians' guide to anti-inflammatory therapy (reproduced from reference [15], with permission)
No or low NSAID gastrointestinal risk NSAID gastrointestinal risk
No cardiovascular risk (without aspirin) Nonselective NSAID (cost consideration) COX-2 selective inhibitor or nonselective NSAID and 
proton-pump inhibitor
COX-2 selective inhibitor and proton-pump inhibitor for 
those with prior GI bleeding
Cardiovascular risk (with aspirin) Naproxena Proton-pump inhibitor irrespective of NSAID
Addition of proton-pump inhibitor if 
gastrointestinal risk of aspirin/NSAID 
combination warrants gastroprotection
Naproxen if CV risk outweighs GI risk
COX-2 selective inhibitor and proton-pump inhibitor for 
those with previous GI bleeding
COX = cyclooxygenase; CV = cardiovascular; GI = gastrointestinal; NSAID = nonsteroidal anti-inflammatory drug.
aNonselective or selective (low-dose) inhibitor without established aspirin interaction if naproxen is ineffective.
Misoprostol at full dose (200 μg four times a day) may be substituted for proton-pump inhibitor.Osteopathic Medicine and Primary Care 2008, 2:2 http://www.om-pc.com/content/2/1/2
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A patient with established CV risk factors (taking aspirin
for CV prophylaxis) who is at minimal risk of NSAID-
induced GI complications may use naproxen or another
NSAID without established aspirin interaction. A PPI may
be added to this regimen should the combination of aspi-
rin and NSAID warrant gastroprotection. Patients with
established CV and GI risk factors should receive a PPI to
be used in conjunction with NSAIDs. If the CV risk factors
outweigh the GI risk factors, naproxen is recommended.
As above, in a patient who has had previous GI bleeding,
the clinician should suggest the use of a COX-2 selective
inhibitor.
Additional recommendations include monitoring blood
pressure and cardiac function in patients with hyperten-
sion. In diabetic patients receiving sulfonylureas and
NSAIDs (including aspirin), routine checks for signals of
increased hypoglycemia should be performed. All patients
should be educated on potential drug interactions that
may occur with OTC analgesics and prescription medica-
tions.
Conclusion
Because many patients self-medicate with OTC analgesics
and are unaware of potentially dangerous drug interac-
tions, proper counseling on the appropriate use of these
agents can help minimize adverse effects and ensure pos-
itive clinical outcomes.
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